Surface TREM2 on circulating M-MDSCs as a novel prognostic factor for adults with treatment-naïve diffuse large B-cell lymphoma

Table 1 Characteristics of 100 patients with treatment-naïve diffuse large B-cell lymphoma

Number of patients (%)	Number of patients (%). Median of value [interquartile-range]
Age, years	70 [60–79]
> 70	50 (50%)
≤ 70	50 (50%)
Sex
Male	64 (64%)
Hepatitis B carrier^a	14 (14%)
Ann-Arbor stage
I	19 (19%)
II	21 (21%)
III	20 (20%)
IV	40 (40%)
IPI score
0	6 (6%)
1	19 (19%)
2	16 (16%)
3	26 (26%)
4	19 (19%)
5	14 (14%)
BM involvement	26 (26%)
Complex karyotype	9 (9%)
Bulky mass > 7.5 cm	36 (36%)
Hemophagocytic lymphohistiocytosis^b	3 (3%)
Cell of origin by IHC stain^c
GCB type^d	26 (26%)
Non-GCB type	74 (74%)
Double-expressor lymphoma^e	41 (41%)
Epstein-Barr virus-positive diffuse large B-cell origin	6 (6%)
Transformation from previous indolent lymphoma^f	5 (5%)
T cells in PB
CD4⁺ T cells (absolute count/µL)	506 [278–772]
CD8⁺ T cells (absolute count/µL)	390 [269–529]
Ratio of CD4⁺/CD8⁺ T cells	1.38 [0.84–2.08]
Percentage of M-MDSC among CD45⁺ cells in PB	0.96% [0.38–1.95]
Frontline treatment
Induction immunochemotherapy followed by HDC/ASCT	17 (17%)
Induction immunochemotherapy only	71 (71%)
Failed or incomplete induction	12 (12%)
Induction regimen of immunochemotherapy
R & CHOP-like	76 (76%)
R & EPOCH	19 (19%)
R & Hyper-CVAD	2 (2%)
Other^g	3 (3%)
Treatment response after frontline treatment
CR	82 (82%)
PR	6 (6%)
SD/PD/Death^h	0/7/5 (0/7/5%)

^aFourteen patients with positive HBs antigen; 78 patients with positive anti-HBc IgG antibody
^bDefined according to the HLH-2004 criteria
^cDefined according to the Hans algorithm
^dExamined all 26 GCB-type DLBCL patients for FISH of MYC, BCL2, and BCL6: six patients diagnosed as double-hit lymphoma, one patient undetermined due to severely crushing samples
^eDefined as the expression of MYC and BCL2 in lymphoma cells ≧40% and ≧50%, respectively
^fTwo patients from follicular lymphoma; two patients from marginal zone lymphoma; one patient from mature B cell neoplasm
^gThree patients died before initiating immunochemotherapy: two received rituximab, and one received merely steroid
^hFive patients died before response evaluation
BM, bone marrow; CR, complete remission; GCB, germinal center B cell; HDC/ASCT, high-dose chemotherapy and autologous stem cell transplantation; IHC, immunohistochemistry; IPI, international prognostic index; M-MDSCs, monocytic myeloid-derived suppressor cells; PB, peripheral blood; PD, progressive disease; PR, partial remission; R, rituximab; SD, stable disease

ISSN: 2162-3619